Boston University School of Medicine/Boston Medical Center, Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, 801 Massachusetts Avenue, 2nd Floor, Boston, MA, 02118, United States.
Kaiser Permanente, 2238 Geary Blvd, San Francisco, CA, 94115, United States.
Drug Alcohol Depend. 2018 Aug 1;189:166-171. doi: 10.1016/j.drugalcdep.2018.05.010. Epub 2018 Jun 19.
Guidelines recommend long-term treatment for opioid use disorder including the use of buprenorphine; however, many patients desire to eventually taper off. This study examines the prevalence and patient characteristics of patients that voluntarily taper off buprenorphine.
This is a 12-year retrospective cohort study of adults on buprenorphine in a large urban safety-net primary care practice. The primary outcome was completion of a voluntary buprenorphine taper, which was further characterized as a medically supervised or unsupervised taper. The secondary outcome was re-engagement in care after taper. Descriptive statistics and estimated proportions of both taper completion and re-engagement in treatment were calculated using Kaplan-Meier estimates.
The study sample included 1308 patients with a median follow-up time of 316 days; 48 patients were observed to taper off buprenorphine during the study period, with an estimated proportion of 15% (95%CI: 10%-21%) based on Kaplan Meier analyses. Less than half of the tapers, 45.8% (22/48), were medically supervised. Thirteen of the 48 patients subsequently, re-engaged in buprenorphine treatment (estimated proportion 61%, 95%CI: 27%-96%), based on Kaplan-Meier analyses with median follow-up time of 490 days.
Despite the fact that many patients desire to discontinue buprenorphine, a minority had a documented taper. Among those who tapered, more than half did so unsupervised by the clinic and a majority of those who tapered off returned to buprenorphine treatment within two years. As many patients are unable to successfully taper off buprenorphine, the medical community must work to address any barriers to long-term maintenance.
指南建议对阿片类药物使用障碍进行长期治疗,包括使用丁丙诺啡;然而,许多患者希望最终能够逐渐减少药物剂量。本研究调查了自愿减少丁丙诺啡剂量的患者的患病率和患者特征。
这是一项为期 12 年的回顾性队列研究,对象为在一家大型城市初级保健机构中使用丁丙诺啡的成年人。主要结局是完成自愿丁丙诺啡减量,进一步分为医学监督或非监督减量。次要结局是减量后重新开始治疗。使用 Kaplan-Meier 估计值计算两种减量完成和重新开始治疗的比例的描述性统计和估计比例。
研究样本包括 1308 名患者,中位随访时间为 316 天;在研究期间,有 48 名患者观察到减少丁丙诺啡的剂量,根据 Kaplan-Meier 分析,估计比例为 15%(95%CI:10%-21%)。不到一半的减量者(45.8%,22/48)接受了医学监督。在 48 名患者中,有 13 名随后重新开始接受丁丙诺啡治疗(根据 Kaplan-Meier 分析,估计比例为 61%,95%CI:27%-96%),中位随访时间为 490 天。
尽管许多患者希望停止使用丁丙诺啡,但只有少数人有记录的减量。在那些减量的患者中,超过一半是在没有诊所监督的情况下进行的,而且大多数减量的患者在两年内又重新开始使用丁丙诺啡治疗。由于许多患者无法成功地减少丁丙诺啡的剂量,医疗界必须努力解决长期维持治疗的任何障碍。